Meta-IQ is a Danish Biotech company, dedicated to the development of innovative treatment for CNS diseases, including Secondary progressive multiple sclerosis (SP-MS), ALS, Parkinson’s Diseases and Depression. Meta-IQ will as the first indication focus on patients with SP-MS.
The synergy of systems work: In systemic thinking one tries to look at a problem from above and tries to identify all factors involved in the problem, identify how these factors influence each other and how they give meaning to each other. The scientific basis for the development of the drug candidate is, as symbolized by the Meta-IQ logo, that diseases develop due to an imbalance in the immunological, psychological and metabolic state of a person which is based upon the genetic background for every individual.
Meta-IQ is founded by Dr. John D. Nieland Vestergaard and M.Sc. Jette G. K. Nieland. Jette G. K. Nieland has international experience as a clinical and business psychologist with systemic thinking as basis. Jette G. K. Nieland has her M.Sc. in psychology from the University of Aarhus and systemic thinking from JFK University CA. John D. Nieland Vestergaard has an international experience in biotech and pharma and he has a Ph.D. in medicine from the Free University, Amsterdam University, Faculty of Medicine.
In September 2011, the group of Manchester of the University of California in San Diego confirmed the data of Meta-IQ in Multiple Sclerosis. Dr. Marianne Manchester confirmed that Meta-IQ’s drug candidate restores the myelin sheet that protects the individual neurons, and thereby cures the laming of the muslces in mice. Article UCSD Etomoxir in MS.
Dr. Angelique Corthals
Asst Professor, Forensic and Biomedical Science, City University of New York
Prof. Dr. Roland Martin and Dr. Sven Shipling
Supervisors and Clinical Managers in MS, University of Zurich, Switzerland
Jette G.K. Nieland
Chairman of the Board
Lawyer (Supreme Court)